| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Peter T Tsai, Court Hull, YunXiang Chu, Emily Greene-Colozzi, Abbey R Sadowski, Jarrett M Leech, Jason Steinberg, Jacqueline N Crawley, Wade G Regehr, Mustafa Sahi. Autistic-like behaviour and cerebellar dysfunction in Purkinje cell Tsc1 mutant mice. Nature. vol 488. issue 7413. 2012-10-11. PMID:22763451. |
tuberous sclerosis complex (tsc) is a genetic disorder with high rates of comorbid asds that result from mutation of either tsc1 or tsc2, whose protein products dimerize and negatively regulate mammalian target of rapamycin (mtor) signalling. |
2012-10-11 |
2023-08-12 |
mouse |
| Delia M Talos, Hongyu Sun, Xiangping Zhou, Erin C Fitzgerald, Michele C Jackson, Peter M Klein, Victor J Lan, Annelise Joseph, Frances E Jense. The interaction between early life epilepsy and autistic-like behavioral consequences: a role for the mammalian target of rapamycin (mTOR) pathway. PloS one. vol 7. issue 5. 2012-09-17. PMID:22567115. |
the mammalian target of rapamycin (mtor) modulates protein translation and is dysregulated in tuberous sclerosis complex, a disorder characterized by epilepsy and autism. |
2012-09-17 |
2023-08-12 |
rat |
| David Neal Franz, Brian D Weis. Molecular therapies for tuberous sclerosis and neurofibromatosis. Current neurology and neuroscience reports. vol 12. issue 3. 2012-09-04. PMID:22544507. |
neurofibromatosis type 1 (nf1) and tuberous sclerosis complex (tsc) are autosomal-dominant genetic disorders that result from dysregulation of the pi3k/akt/mammalian target of rapamycin (mtor) pathway. |
2012-09-04 |
2023-08-12 |
Not clear |
| Thomas F O'Brien, Xiao-Ping Zhon. The role and regulation of mTOR in T-lymphocyte function. Archivum immunologiae et therapiae experimentalis. vol 60. issue 3. 2012-08-30. PMID:22484804. |
furthermore, we highlight the importance of tight control of mtor signaling by tuberous sclerosis complex 1 for t-cell homeostasis, and the regulation of mtor signaling by diacylglycerol kinases and the rasgrp1-ras-erk1/2 pathway in the context of tcr signaling. |
2012-08-30 |
2023-08-12 |
Not clear |
| Alexander A Sosunov, Xiaoping Wu, Robert A McGovern, David G Coughlin, Charles B Mikell, Robert R Goodman, Guy M McKhan. The mTOR pathway is activated in glial cells in mesial temporal sclerosis. Epilepsia. vol 53 Suppl 1. 2012-07-16. PMID:22612812. |
mutations in mtor cause tuberous sclerosis complex (tsc), a condition that is characterized by developmental brain malformations (cortical tubers) and epilepsy. |
2012-07-16 |
2023-08-12 |
human |
| Christiane Fuchs, Margit Rosner, Helmut Dolznig, Mario Mikula, Nina Kramer, Markus Hengstschläge. Tuberin and PRAS40 are anti-apoptotic gatekeepers during early human amniotic fluid stem-cell differentiation. Human molecular genetics. vol 21. issue 5. 2012-07-05. PMID:22090422. |
here, we report that sirna-mediated knockdown of the endogenous tuberous sclerosis complex-2 (tsc2) gene product tuberin or of proline-rich akt substrate of 40 kda (pras40), the two major negative regulators of mammalian target of rapamycin (mtor), leads to massive apoptotic cell death during eb development of human afs cells without affecting the endodermal, mesodermal and ectodermal cell differentiation spectrum. |
2012-07-05 |
2023-08-12 |
human |
| Baishen Chen, Ju Chen, Michael G House, Kevin J Cullen, Kenneth P Nephew, Zhongmin Gu. Role of neurofilament light polypeptide in head and neck cancer chemoresistance. Molecular cancer research : MCR. vol 10. issue 3. 2012-07-05. PMID:22246235. |
furthermore, nefl physically associated with tuberous sclerosis complex 1 (tsc1), a known inhibitor of the mtor pathway, and nefl downregulation led to functional activation of mtor pathway and consequentially conferred cisplatin resistance. |
2012-07-05 |
2023-08-12 |
human |
| Hongjie Pan, Thomas F O'Brien, Ping Zhang, Xiao-Ping Zhon. The role of tuberous sclerosis complex 1 in regulating innate immunity. Journal of immunology (Baltimore, Md. : 1950). vol 188. issue 8. 2012-06-21. PMID:22412198. |
the tuberous sclerosis complex 1 (tsc1) is a tumor suppressor that inhibits the mammalian target of rapamycin (mtor). |
2012-06-21 |
2023-08-12 |
Not clear |
| Pei Wang, Yun-Feng Guan, Hui Du, Qi-Wei Zhai, Ding-Feng Su, Chao-Yu Mia. Induction of autophagy contributes to the neuroprotection of nicotinamide phosphoribosyltransferase in cerebral ischemia. Autophagy. vol 8. issue 1. 2012-06-06. PMID:22113203. |
immunochemistry (lc3-ii), electron microscope and immunoblotting assays (lc3-ii, beclin-1, mammalian target of rapamycin [mtor], s6k1 and tuberous sclerosis complex-2 [tsc2]) were performed to assess autophagy. |
2012-06-06 |
2023-08-12 |
rat |
| José Antonio Troca-Marín, Alexandra Alves-Sampaio, María Luz Montesino. Deregulated mTOR-mediated translation in intellectual disability. Progress in neurobiology. vol 96. issue 2. 2012-06-05. PMID:22285767. |
hyperactivation of mtor has been recently reported in mouse models of fragile x and tuberous sclerosis, two important causes of intellectual disability. |
2012-06-05 |
2023-08-12 |
mouse |
| Wei Chen, Tao Ma, Xu-ning Shen, Xue-feng Xia, Guo-dong Xu, Xue-li Bai, Ting-bo Lian. Macrophage-induced tumor angiogenesis is regulated by the TSC2-mTOR pathway. Cancer research. vol 72. issue 6. 2012-05-14. PMID:22287548. |
in human peripheral monocytes stimulated by lipopolysaccharide, mtor was inhibited by rapamycin or activated by rna interference-mediated knockdown of the mtor repressor tuberous sclerosis complex 2 (tsc2). |
2012-05-14 |
2023-08-12 |
human |
| Ricardo J Komotar, Robert M Starke, E Sander Connolly, Michael B Sist. mTOR inhibitors in the treatment of subependymal giant-cell astrocytomas associated with tuberous sclerosis. Neurosurgery. vol 68. issue 4. 2012-05-08. PMID:21792104. |
mtor inhibitors in the treatment of subependymal giant-cell astrocytomas associated with tuberous sclerosis. |
2012-05-08 |
2023-08-12 |
Not clear |
| Emmanuel Raffo, Antonietta Coppola, Tomonori Ono, Stephen W Briggs, Aristea S Galanopoulo. A pulse rapamycin therapy for infantile spasms and associated cognitive decline. Neurobiology of disease. vol 43. issue 2. 2012-05-07. PMID:21504792. |
overactivation of the torc1 complex of the mtor pathway is implicated in the pathogenesis of certain genetic and acquired disorders that are linked with infantile spasms, like tuberous sclerosis. |
2012-05-07 |
2023-08-12 |
rat |
| Guido Martignoni, Franco Bonetti, Marco Chilosi, Matteo Brunelli, Diego Segala, Mahul B Amin, Pedram Argani, John N Eble, Stefano Gobbo, Maurizio Pe. Cathepsin K expression in the spectrum of perivascular epithelioid cell (PEC) lesions of the kidney. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. vol 25. issue 1. 2012-05-01. PMID:21874011. |
it has been demonstrated that most of these lesions are determined by mutations affecting genes of the tuberous sclerosis complex, tuberous sclerosis 1 (tsc1) and tuberous sclerosis 2 (tsc2), with eventual deregulation of the rheb/mtor/rps6kb2 pathway, and it has been observed that some pecomas regressed during sirolimus therapy, an mtor inhibitor. |
2012-05-01 |
2023-08-12 |
Not clear |
| Jan-Mendelt Tillema, James L Leach, Darcy A Krueger, David Neal Fran. Everolimus alters white matter diffusion in tuberous sclerosis complex. Neurology. vol 78. issue 8. 2012-04-23. PMID:22262746. |
diffusion tensor imaging (dti) analysis was performed on patients with tuberous sclerosis complex (tsc) to investigate potential changes in normal-appearing white matter after treatment with everolimus, a mammalian target of rapamycin (mtor) inhibitor. |
2012-04-23 |
2023-08-12 |
Not clear |
| Laura Magri, Marco Cambiaghi, Manuela Cominelli, Clara Alfaro-Cervello, Marco Cursi, Mauro Pala, Alessandro Bulfone, Jose Manuel Garcìa-Verdugo, Letizia Leocani, Fabio Minicucci, Pietro Luigi Poliani, Rossella Gall. Sustained activation of mTOR pathway in embryonic neural stem cells leads to development of tuberous sclerosis complex-associated lesions. Cell stem cell. vol 9. issue 5. 2012-04-09. PMID:22056141. |
sustained activation of mtor pathway in embryonic neural stem cells leads to development of tuberous sclerosis complex-associated lesions. |
2012-04-09 |
2023-08-12 |
mouse |
| Thomas G Sommermann, Kathleen O'Neill, David R Plas, Ellen Cahir-McFarlan. IKKβ and NF-κB transcription govern lymphoma cell survival through AKT-induced plasma membrane trafficking of GLUT1. Cancer research. vol 71. issue 23. 2012-04-04. PMID:21987722. |
activated nf-κb promoted akt-mediated phosphorylation of the glut1 regulator, akt substrate of 160kd (as160), but was not required for akt phosphorylation of the mtor regulator tuberous sclerosis 2 (tsc2). |
2012-04-04 |
2023-08-12 |
Not clear |
| Falguni Das, Nandini Ghosh-Choudhury, Nirmalya Dey, Chandi Charan Mandal, Lenin Mahimainathan, Balakuntalam S Kasinath, Hanna E Abboud, Goutam Ghosh Choudhur. Unrestrained mammalian target of rapamycin complexes 1 and 2 increase expression of phosphatase and tensin homolog deleted on chromosome 10 to regulate phosphorylation of Akt kinase. The Journal of biological chemistry. vol 287. issue 6. 2012-03-25. PMID:22184110. |
tuberous sclerosis complex 2 (tsc2) and phosphatase and tensin homolog deleted on chromosome 10 (pten) function to block growth factor-induced mammalian target of rapamycin (mtor) signaling and are mutated in autosomal dominant hamartoma syndromes. |
2012-03-25 |
2023-08-12 |
mouse |
| Klemens Budde, Jens Gaedek. Tuberous sclerosis complex-associated angiomyolipomas: focus on mTOR inhibition. American journal of kidney diseases : the official journal of the National Kidney Foundation. vol 59. issue 2. 2012-03-22. PMID:22130643. |
tuberous sclerosis complex-associated angiomyolipomas: focus on mtor inhibition. |
2012-03-22 |
2023-08-12 |
Not clear |
| Thomas Weichhar. Mammalian target of rapamycin: a signaling kinase for every aspect of cellular life. Methods in molecular biology (Clifton, N.J.). vol 821. 2012-03-16. PMID:22125056. |
dysregulation of the mtor pathway is frequently observed in various cancers and in genetic disorders, such as tuberous sclerosis complex or cystic kidney disease. |
2012-03-16 |
2023-08-12 |
Not clear |